United Therapeutics Announces Positive Tyvaso Study Results

Pivotal TETON-1 trial meets primary endpoint for treatment of pulmonary hypertension.

Mar. 30, 2026 at 12:25pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the delicate, ghostly structure of human lungs, conceptually illustrating the potential of a new treatment for pulmonary hypertension.The successful TETON-1 trial brings United Therapeutics closer to providing a new inhaled therapy for the treatment of debilitating pulmonary hypertension.Silver Spring Today

United Therapeutics Corporation has announced that its pivotal TETON-1 study of Tyvaso, a treatment for pulmonary hypertension, has met its primary endpoint. The positive results from this late-stage clinical trial represent an important milestone in the development of this therapy for patients living with this serious and progressive cardiovascular disease.

Why it matters

Pulmonary hypertension is a debilitating condition that can lead to heart failure if left untreated. The successful TETON-1 study brings United Therapeutics one step closer to potentially providing a new treatment option for the estimated 50,000 Americans living with this chronic and life-threatening illness.

The details

The TETON-1 study evaluated the safety and efficacy of Tyvaso, an inhaled formulation of the drug treprostinil, in patients with pulmonary hypertension. The trial's primary endpoint, which measured improvement in exercise capacity, was met with statistical significance. United Therapeutics plans to submit the data to regulatory authorities for potential approval of Tyvaso as a new therapy.

  • The TETON-1 pivotal study was conducted from 2023 to 2026.

The players

United Therapeutics Corporation

A biopharmaceutical company focused on developing therapies for patients with chronic and life-threatening conditions, including pulmonary hypertension.

Tyvaso

An inhaled formulation of the drug treprostinil developed by United Therapeutics as a treatment for pulmonary hypertension.

Got photos? Submit your photos here. ›

What’s next

United Therapeutics plans to submit the TETON-1 data to regulatory authorities for potential approval of Tyvaso as a new therapy for pulmonary hypertension.

The takeaway

The positive results from the TETON-1 study represent an important advancement in the development of new treatment options for the thousands of Americans living with the debilitating effects of pulmonary hypertension.